Rein Therapeutics, Inc. Common Stock RNTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | ||
| $11.03M-22.6% | $14.25M+257% | $3.99M-77.8% | $17.97M+5.6% | ||
| $10.9M-21.4% | $13.86M+22.1% | $11.36M+17.3% | $9.68M+0.9% | ||
| $50.63M-22.2% | $65.11M+300% | $16.28M-41.1% | $27.65M+3.9% | ||
| -$50.63M+22.2% | -$65.11M-300% | -$16.28M+41.1% | -$27.65M-3.9% | ||
| —— | $685K+15.5% | $593K+86.5% | $318K-27.9% | ||
| -$712K+53.9% | -$1.54M— | $0— | —— | ||
| -$49.87M+20.7% | -$62.88M-300% | -$15.73M+42.4% | -$27.33M-4.5% | ||
| -$1.96+48.1% | -$3.78-10.9% | -$3.41+43.4% | -$6.02-2.4% | ||
| -$50.63M+22.2% | -$65.11M-300% | -$16.28M+41.1% | -$27.65M-3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rein Therapeutics, Inc. Common Stock profitable?
- Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.
- What is Rein Therapeutics, Inc. Common Stock's earnings per share?
- Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.
- Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.